our Premium Content: News alerts, weekly reports and conference planners

GENE:

DRD2 (Dopamine Receptor D2)

News alerts, weekly reports and conference planners

15d

DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut. (PubMed, Adv Sci (Weinh))

The depletion of bacteria systemically, microglial depletion or HMGB1 inhibitor ethyl pyruvate rescued prolactinomas. Our findings suggest that DRD2 deficiency underlies pituitary adenoma dependent on Escherichia coli translocation from the gut and activating microglia GSDMD/ HMGB1/MAPK pathway, and provide a novel preclinical rationale for antimicrobial agents, microglial depletion, or HMGB1 inhibitor ethyl pyruvate for the treatment of pituitary adenoma.

15 days ago

Journal

HMGB1 (High Mobility Group Box 1) • DRD2 (Dopamine Receptor D2)

17d

Decoding the immunopharmacological basis of ECT-induced clozapine level elevation: Insights from a Quantitative Systems Pharmacology model. (PubMed, Eur J Pharmacol)

The QSP model provides a robust, mechanistically plausible explanation for the observed ECT-clozapine interaction, identifying the inflammatory cascade as the critical driver of impaired clozapine metabolism. The model serves as a powerful tool for simulating patient risk and provides a quantitative foundation for developing personalized, model-informed dosing strategies to enhance the safety of this crucial concomitant therapy.

17 days ago

Journal

IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CRP (C-reactive protein) • DRD2 (Dopamine Receptor D2)

26d

Detection of Structural Changes in G-Quadruplex-Forming DNA Oligonucleotides via DNA Methylation Based on Luminol Chemiluminescence Catalyzed by Myoglobin. (PubMed, Biosensors (Basel))

Versatility was further confirmed using the sequence from the dopamine receptor D2 (DRD2) gene promoter, where the methylation similarly induced distinct topological and functional changes. This is the first study to directly link the epigenetic state of a G4-forming DNA sequence to a protein-mediated enzymatic output, offering a framework for simple, rapid, and highly adaptable biosensors for research and clinical applications.

26 days ago

Journal

BCL2 (B-cell CLL/lymphoma 2) • DRD2 (Dopamine Receptor D2) • MB (Myoglobin)

2ms

Dordaviprone in H3K27M-mutant diffuse midline glioma: an editorial on emerging targeted therapy. (PubMed, Ann Med Surg (Lond))

Treatment was well tolerated, with only grade 1-2 adverse events reported. Larger randomized studies are needed to validate efficacy and long-term safety.

2 months ago

Journal

DRD2 (Dopamine Receptor D2)

Modeyso (dordaviprone)

3ms

G protein-coupled receptor digital twins for precision and personalized medicine. (PubMed, Comput Struct Biotechnol J)

By bridging molecular insights with clinical applications, digital twins offer a powerful platform for precision GPCR medicine, promising improved therapeutic outcomes through individualized treatment strategies. The triumvirate of digital twins, QSP, and AI will likely revolutionize GPCR-targeted therapies, paving the way for a new era of precision medicine while highlighting the need for ethical and technical advancements to maximize their clinical impact.

3 months ago

Review • Journal

CXCR4 (Chemokine (C-X-C motif) receptor 4) • DRD2 (Dopamine Receptor D2)

3ms

Drug Repurposing Screen Identifies Pimozide as a ROS-Inducing Therapy With Anti-Tumor Efficacy in HNSCC PDX Models. (PubMed, Cancer Sci)

Notably, pimozide exhibited anti-tumor effects as a monotherapy and in combination with paclitaxel at clinically relevant doses. While tumor volume reduction in the combination group was not statistically greater than that in the monotherapy group, fluorescence immunohistochemistry revealed a marked decrease in undifferentiated tumor cells, indicating enhanced therapeutic effects of combination treatment. Taken together, these findings indicate that pimozide is a promising candidate for repurposing as a novel therapeutic agent against HNSCC.

3 months ago

Journal

STAT3 (Signal Transducer And Activator Of Transcription 3) • DRD2 (Dopamine Receptor D2) • EGR1 (Early Growth Response 1)

paclitaxel

3ms

Netrin-1 Inhibits Neuroinflammation by Modulating DRD2/GSK3β Signaling and Suppressing ROS in a Parkinson's Disease Model. (PubMed, CNS Neurosci Ther)

These findings suggest that Netrin-1 protects dopaminergic neurons by regulating neuroinflammation, preserving DRD2 signaling, and inhibiting phosphorylation of GSK3β at Tyr216, thereby offering potential as a therapeutic agent for dopaminergic neurodegeneration.

3 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • SNCA (Synuclein Alpha) • DRD2 (Dopamine Receptor D2) • NTN1 (Netrin 1)

3ms

Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist. (PubMed, Brain Tumor Pathol)

In a rare case of metastatic Gn-PitNET, cabergoline was associated with tumor stability and hormone control. Further studies may clarify whether DRD2 expression can help predict DA responsiveness in refractory tumors.(200/200 words).

3 months ago

Journal

DRD2 (Dopamine Receptor D2)

3ms

The neuromodulatory effects of Pueraria lobata roots and Puerarin on the dopamine system. (PubMed, Food Sci Biotechnol)

In contrast, PUE treatment reduced TH expression and downregulated DRD1 and DRD2 expression without altering DAT levels, indicating a suppressive effect on the dopaminergic system. These findings demonstrate that PL and PUE exert distinct modulatory effects on dopaminergic signaling-PL enhancing and PUE inhibiting DA activity-highlighting their potential therapeutic applications for neurodegenerative disorders associated with dopaminergic dysfunction.

3 months ago

Journal

DRD1 (Dopamine Receptor D1) • DRD2 (Dopamine Receptor D2)

4ms

Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment. (PubMed, Eur J Endocrinol)

Prolactinomas and somatotropinomas were classified into distinct transcriptomic groups. Resistance to medical therapies was linked to distinct tumor subtypes, suggesting distinct mechanisms of resistance.

4 months ago

Journal

SSTR (Somatostatin Receptor) • SOX2 • SSTR2 (Somatostatin Receptor 2) • GNAS (GNAS Complex Locus) • DRD2 (Dopamine Receptor D2)

4ms

Dynamic profiles of 25 serum biomarkers in acute myocardial infarction. (PubMed, Front Cardiovasc Med)

They returned to baseline levels at 12 h and 2 h respectively, followed by rapid decreases again. This study is the first to systematically characterize the dynamic profiles of 25 serum biomarkers following AMI in rats, revealing that: (1) IL-1β, S100A8, BNP, SLC31A1 and Cys may serve as an ultra-early (1 h) diagnostic panel (increase of over 70% at 1 h); (2) the delayed elevation of α-SMA and CXCL16 may be associated with the initiation of myocardial repair; (3) the suppression of Lp-α and D2D might reflect compensatory protective mechanisms.

4 months ago

Journal

IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • S100A8 (S100 Calcium Binding Protein A8) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • CCL2 (Chemokine (C-C motif) ligand 2) • MMP9 (Matrix metallopeptidase 9) • CCR2 (C-C Motif Chemokine Receptor 2) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • ANPEP (Alanyl Aminopeptidase, Membrane) • CRP (C-reactive protein) • CTGF (Connective tissue growth factor) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • DRD2 (Dopamine Receptor D2) • SLC31A1 (Solute Carrier Family 31 Member 1)

5ms

Epigenetic modifications and transgenerational inheritance in women victims of violence (EWVV). (PubMed, Environ Epigenet)

This can help to identify direct links or epigenetic marks useful for optimizing personalized interventions encompassing the genetic, neuropsychiatric, social, and forensic medicolegal fields. Future research should be conducted with extreme caution to evaluate the long-term effects of such strategies and assess whether the immediate observed effects are maintained.

5 months ago

Review • Journal

IGF2 (Insulin-like growth factor 2) • ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1) • DRD2 (Dopamine Receptor D2) • FKBP5 (FKBP Prolyl Isomerase 5) • SLC6A4 (Solute Carrier Family 6 Member 4)